1-(4-Nitrophenyl)-2-piperidinone Chemical Properties

Melting point:

97.0 to 101.0 °C

Boiling point:

480.9±28.0 °C(Predicted)

Density 

1.295

storage temp. 

Sealed in dry,Room Temperature

solubility 

Chloroform (Slightly),Ethyl Acetate (Slightly)

pka

-3.84±0.20(Predicted)

form 

Solid

color 

Off-White to Yellow

InChI

InChI=1S/C11H12N2O3/c14-11-3-1-2-8-12(11)9-4-6-10(7-5-9)13(15)16/h4-7H,1-3,8H2

InChIKey

VPCQXIGQMFWXII-UHFFFAOYSA-N

SMILES

N1(C2=CC=C([N+]([O-])=O)C=C2)CCCCC1=O

Safety Information

HS Code 

2933.79.1500

1-(4-Nitrophenyl)-2-piperidinone Usage And Synthesis

Uses

1-(4-Nitrophenyl)-2-piperidinone is used in the synthesis of inhibitors of blood coagulation factor Xa.

Synthesis

5-Chloro-N-(4-nitrophenyl)pentanamide (72.3 g, 0.28 mol) was used as a raw material, which was mixed with K2CO3 and DMSO (360 mL) and the reaction was stirred at 80 °C for 6 hours. Upon completion of the reaction, the mixture was cooled to room temperature and subsequently poured into ice water (200 mL). The resulting precipitate was collected by filtration, washed with water and dried under reduced pressure to afford the target product 1-(4-nitrophenyl)-2-piperidone as a yellow powder (55.7 g, 89.6% yield). The melting point of the product was 96.4-98.3 °C; mass spectrum (ESI) m/z (%): 221.08 [M + H]+.

References

[1] Bioorganic and Medicinal Chemistry, 2016, vol. 24, # 21, p. 5646 - 5661
[2] Patent: CN104650072, 2016, B. Location in patent: Paragraph 0122; 0125; 0129; 0130
[3] Patent: US2017/15663, 2017, A1. Location in patent: Paragraph 0141
[4] Synthetic Communications, 2013, vol. 43, # 1, p. 72 - 79
[5] Bioorganic and Medicinal Chemistry, 2017, vol. 25, # 10, p. 2800 - 2810

1-(4-Nitrophenyl)-2-piperidinone(38560-30-4)Related Product Information

• Apixaban
• (4,4'‐didodecyl‐2,2'‐ bithiophene‐5,5'‐ diyl)bis(triMethylstann ane)
• 5-chloro-N-(4-(5-morpholino-6-oxo-3,6-dihydropyridin-1(2H)-yl)phenyl)pentanamide
• Apixaban IMpurity 6
• Apixaban IMpurity(
• 1-(4-chlorophenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxaMide
• 1-(4-Methoxyphenyl)-6-(4-iodophenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester
• Apixaban IMpurity 3
• Apixaban Impurity 12
• 1-(4-Methoxyphenyl)-6-(4-(2-Methyl-6-oxopiperidin-1-yl)phenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxaMide
• Apixaban-13C-D3
• 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid
• Acetic acid, 2-chloro-2-[2-(4-methoxyphenyl)hydrazinylidene], ethyl ester
• 3-Morpholino-1-(4-(2-oxopiperidin-1-yl)phenyl)-5,6-dihydropyridin-2(1H)-one
• 3-Morpholino-1-(4-nitrophenyl)-5,6-dihydropyridin-2(1H)-one
• 1-(4-AMinophenyl)-5,6-dihydro-3-(4-Morpholinyl)-2(1h)-pyridinone
• 1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester
• 4,5,6,7-Tetrahydro-1-(4-methoxyphenyl)-6-[4-(5-methyl-2-oxo-1-piperidinyl)phenyl]-7-oxo-1H-pyrazolo[3,4-c]pyridine-3-carboxamide